682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation
oleh: Yun Wang, Ran Reshef, Gavin MacBeath, Jim Murray, Debora Barton, Erica Buonomo, Shrikanta Chattopadhyay, Monzr Al Malki, Alla Keyzner, Hyung C Suh, Aasiya Matin, Nina Abelowitz
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2023-11-01 |
Deskripsi
No description available for this item.